Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity.
Yu X, Lu D, Qi X, Lin H, Holloman BL, Jin F, Xu L, Ding L, Peng W, Wang MC, Chen X, Wang J.
Yu X, et al. Among authors: lin h.
bioRxiv [Preprint]. 2024 Mar 29:2024.03.25.586133. doi: 10.1101/2024.03.25.586133.
bioRxiv. 2024.
PMID: 38590362
Free PMC article.
Updated.
Preprint.